Evaluation of the Adverse Event of Nimotuzumab Combined Therapy in Patients with Advanced Carcinoma
L. Chen,H. Chen,X. Zhang,B. Liang,G. Zhang,G. Ma,J. Zheng
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.e13081
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:e13081 Background: To evaluate the adverse events of Nimotuzumab combined with chemotherapy, radiotherapy or chemo-radiotherapy in treatment of advanced carcinomas.METHODSFrom January 2010 until October 2010, 835 patients with pathologically diagnosed malignant tumor, staged between II to ‡W with practical metastasis treated by Nimotuzumab combined with radiotherapy, chemotherapy or chemo-radiotherapy (NCT00983047GNCT074021GNCT985998GNCT01232374GNCT980417GNCT910117GNCT972465GNCT01180166, etc.). Generally, patients were receiving a dose of 45Gy-72Gy radiotherapy. The patients who were mainly receiving combination of chemotherapy program of the platinum's. All patients were receiving 100-200mg of Nimotuzumab once a week at the same time of the other therapies.RESULTSThere were 792 cases' medical records can be analyzed, of which 241 patients have diagnosed as Nasopharyngeal cancer (28.86%), followed by: 153 cases of head and neck cancer (18.32%), etc. Patients aged 37-75 years-old with median age of 63. Male and female ratio was 5:2. Pathology diagnosed of more than 90% was squamous cell carcinoma. Adenosquamous carcinoma and adenocarcinoma were less than 10%. Cancer staged as ‡W, III and II were 38.2%, 53.7% and 10.1%, and with 23.6% of them with metastasis. 22 patients (2.63%) had adverse reactions which doubt as due to Nimotuzumab, including chills and fever in 8 cases (0.96%), rash in 5 cases (0.6%), oral mucositis in 3 cases (0.36%), gastrointestinal symptoms (vomiting or diarrhea) in 2 cases (0.24%), and dizziness in 1 case (0.12%). Patients with significant fatigue, thrombocytopenia, and decreased white blood cell count of the total number of cases of 0.12% (1 case), 0.6% (5 cases) and 0.6% (5 cases). Nimotuzumab caused allergy accounted for only 0.12% (1 case).CONCLUSIONSNimotuzumab combined with chemotherapy, radiotherapy or chemo-radiotherapy for patients with advanced carcinoma is well tolerated and safe, it will not increase the radiotherapy, chemotherapy radiotherapy induced adverse reaction rate and its' degree.